Fig. 4From: Clinical features and treatment outcomes of pediatric Langerhans cell histiocytosis with macrophage activation syndrome-hemophagocytic lymphohistiocytosisProgression-free survival rates for LCH patients with MAS-HLH. A For the whole cohort. B Comparison for patients treated with dabrafenib or second-line chemotherapyBack to article page